Breaking News
August 15, 2018 - Real-time dynamic monitoring of cell’s nucleus for effective cancer screening
August 15, 2018 - Lower rates of Medicare preventive care visits found in racial, ethnic minority older adults
August 15, 2018 - Scientists identify stress hormone as key factor in failure of immune system to inhibit leukemia
August 15, 2018 - Cytoplan introduces three new nutritional supplements
August 15, 2018 - Effective hemorrhage control critical for survival after motorsport accidents
August 15, 2018 - Sygnature Discovery announces ambitious expansion plan with addition of Alderley Park facility
August 15, 2018 - Dietary carbohydrates could lead to osteoarthritis, new study finds
August 15, 2018 - Male tobacco smokers have decreased number of cannabinoid CB1 receptors, study reveals
August 15, 2018 - Scientists explore ways for drug therapies to reach deadly brain tumors
August 15, 2018 - Rethinking fundamental rule of stroke care: ‘Time is brain!’
August 15, 2018 - Scientists reveal role of ‘junk DNA’ in cancer dissemination
August 15, 2018 - Google’s DeepMind AI could soon be diagnosing eye conditions
August 15, 2018 - Scientists trick the brain to embody the prosthetic limb
August 15, 2018 - Researchers focus on uncoupling obesity from diabetes
August 15, 2018 - A class of proteins shown to be effective in reducing drug-seeking behaviors
August 15, 2018 - Gemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene in Pediatric NAFLD
August 15, 2018 - Rheumatoid arthritis in pregnancy associated with low birth weight and premature birth
August 15, 2018 - Study may help increase effectiveness of antibiotics against drug-resistant bacteria
August 15, 2018 - Analyzing resident-to-resident incidents in dementia may hold the key to reducing future fatalities
August 15, 2018 - Robotic walking frame aims to help maintain mobility of older adults
August 15, 2018 - Simple intervention during routine care reduces alcohol consumption in men with HIV
August 15, 2018 - Genetics Home Reference: gout
August 15, 2018 - Scientists ID genesis of disease, focus efforts on shape-shifting tau
August 15, 2018 - OncoThira and NDSU enter into license agreement to develop, market cancer compounds
August 15, 2018 - Scientists unravel the mystery behind ovarian cancer with high-grade serous carcinoma
August 15, 2018 - Common signs that indicate vision problems in children
August 15, 2018 - Removing the cancer label – overhaul in cancer classification proposed
August 15, 2018 - Prams may expose babies and toddlers to more air pollution finds study
August 15, 2018 - Duke researchers track missing T-cells in glioblastoma patients
August 15, 2018 - Cardiac Profiles Up With Exercise, Less Sitting in Early Old Age
August 15, 2018 - Precision medicine offers a glimmer of hope for Alzheimer’s disease
August 15, 2018 - Immunovia’s new blood-based testing platform accurately detects non-small cell lung cancer
August 15, 2018 - New method provides a ‘big picture’ of genetic influences on traits and diseases
August 15, 2018 - Early Onset Type 1 Diabetes Linked to Heart Disease, Shorter Life
August 14, 2018 - SMURF1 provides targeted approach to preventing cocaine addiction relapse
August 14, 2018 - Genetic testing pushed for hereditary high cholesterol disease
August 14, 2018 - Researchers discover new genes involved in Alzheimer’s Disease
August 14, 2018 - Medicare to overhaul ACOs but critics fear fewer participants
August 14, 2018 - Adolescent health projects receive meager percentage of global funding, study finds
August 14, 2018 - University Hospitals Seidman Cancer Center launches new CAR-T therapy trial
August 14, 2018 - In the addiction battle, is forced rehab the solution?
August 14, 2018 - Busting myths about milk – Scope
August 14, 2018 - Platelet-rich plasma does not enhance cartilage formation capabilities of stem cells
August 14, 2018 - Wearable devices and ‘mhealth’ technology emerge as promising tools for better health
August 14, 2018 - Johns Hopkins expert panel develops first set of operation-specific opioid prescribing guidelines
August 14, 2018 - Clinical study suggests new treatment direction for head and neck cancer in heavy smokers
August 14, 2018 - Phase 2 Clinical Data Published Showing Summit’s Ridinilazole Preserved Gut Microbiome of Patients with CDI
August 14, 2018 - Cardiac progenitor cells undergo a cell fate switch to build coronary arteries
August 14, 2018 - Study identifies potential guidance to treat gastric cancer patients
August 14, 2018 - Revealed: The molecular mechanism underlying hypertrophic cardiomyopathy, or “workaholic heart”
August 14, 2018 - Diabetes epidemic in Guatemala driven by aging, not obesity
August 14, 2018 - New technology shows potential to streamline the analysis of proteins
August 14, 2018 - Rethinking the stroke rule ‘time is brain’
August 14, 2018 - Incidence of coronary artery compression in children may be more common than previously thought
August 14, 2018 - Study helps to better understand disease caused by Alpha-1 antitrypsin deficiency
August 14, 2018 - AI platform identifies acute neurological illnesses faster than human diagnosis
August 14, 2018 - American College of Rheumatology receives grants to support development of lupus clinical trials
August 14, 2018 - New study explains why women get more migraines than men
August 14, 2018 - American Heart Association Urges Screen Time Limits for Youth
August 14, 2018 - Brief interventions during routine care reduce alcohol use among men with HIV
August 14, 2018 - New genome analysis could identify people at higher risk of common deadly diseases
August 14, 2018 - NIH grant for Mount Sinai to study use of inhaled corticosteroids for treatment of sickle cell disease
August 14, 2018 - Daicel supplies free nanodiamond samples to international researchers
August 14, 2018 - Switching anti-psychotic drugs in first-episode schizophrenia patients does not improve clinical outcomes
August 14, 2018 - Study to examine whether modulating gut bacteria can improve cardiac function in heart failure patients
August 14, 2018 - AI technology could hold key to improving health services
August 14, 2018 - One out of two children not getting enough nutrients needed for their health
August 14, 2018 - Mono-antiplatelet therapy after aortic heart valve replacements may work as well as two drugs
August 14, 2018 - Aid-in-dying patient chooses his last day
August 14, 2018 - Exercise Really Can Chase Away the Blues, to a Point
August 14, 2018 - Surgical mesh implants may cause autoimmune disorders
August 14, 2018 - Researchers develop revolutionary zebrafish model to gain more insight into bone diseases
August 14, 2018 - Researchers discover secret communication hotline between breast cancers and normal cells
August 14, 2018 - Study examines how a person adapts to visual field loss after stroke
August 14, 2018 - Researchers show how specialized nucleic acid-based nanostructures could help target cancer cells
August 14, 2018 - Reducing opioid prescriptions for one operation can also spill over to other procedures
August 14, 2018 - E-cigarettes not so safe but still better than cigarettes
August 14, 2018 - Researchers find link between common ‘harmless’ virus and cardiovascular damage
August 14, 2018 - Initiation of PIMs associated with higher risk of fracture-specific hospitalizations and mortality
August 14, 2018 - Genetically modified mosquitoes and special bed nets help tackle deadly diseases
Monthly News Roundup – November 2017

Monthly News Roundup – November 2017

image_pdfDownload PDFimage_print

FDA Approves Juluca, a Novel 2-Drug Regimen for HIV-1 Infection

In November, the U.S. Food and Drug Administration (FDA) approved ViiV Healthcare’s Juluca (dolutegravir and rilpivirine), a single-tablet, two-drug regimen of dolutegravir (Tivicay) and rilpivirine (Edurant). Juluca is the first complete treatment regimen containing only two drugs, instead of three or more, for HIV maintenance. Juluca is used in certain adults with suppressed HIV-1 virus on a stable medication regimen for at least six months, with no history of treatment failure and no resistance to the individual components of Juluca. In clinical trials, Juluca was effective in keeping the virus suppressed and was comparable to those who continued their current anti-HIV drugs.

Every 8-Week Fasenra Approved for Severe Eosinophilic Asthma

Eosinophilic asthma patients have limited treatment options and often rely on oral steroids to manage their symptoms, which can lead to serious side effects. This month, the FDA approved AstraZeneca’s Fasenra (benralizumab), an interleukin-5 receptor monoclonal antibody used as an add-on maintenance treatment for severe eosinophilic asthma. It’s given as a subcutaneous injection once every 4 weeks for the first 3 doses, and then once every 8 weeks thereafter. In studies, Fasenra reduced the annual asthma exacerbation rate by up to 51% compared to placebo, and significantly reduced oral steroid use. Adverse events include headache, fever, sore throat and allergic reactions.

Vyzulta: A Dual Mechanism Prostaglandin Analog Approved for Glaucoma

The FDA has now approved Valeant’s Vyzulta (latanoprostene bunod ophthalmic solution, 0.024%), a once-daily treatment for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension. Vyzulta is the first nitric-oxide donating prostaglandin F2α analog for ophthalmic use. The eye drop works by breaking down into two metabolites: latanoprost acid and butanediol mononitrate, both of which help to increase the outflow of aqueous humor. Commonly reported side effects include conjunctival hyperemia (redness), eye irritation or pain. Increased pigmentation of the iris and periorbital tissue and growth of eyelashes can also occur.

First-In-Class Hemlibra is Cleared for Hemophilia A with Inhibitors

Hemlibra (emicizumab-kxwh), from Genentech, is a bispecific factor IXa- and factor X-directed antibody now approved to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A with inhibitors who have developed antibodies called Factor VIII (FVIII) inhibitors. Hemophilia A is an inherited blood-clotting disorder that primarily affects males. Hemlibra is a first-in-class subcutaneous injection that works by bridging other factors in the blood to restore blood clotting. In two clinical studies, there was an 87 percent reduction in the rate of bleeds that needed treatment. Common side effects include injection site reactions, headache, and joint pain (arthralgia).

Abilify MyCite: Swallowed Sensor Tracks If You’ve Taken Your Med

The cost of patient nonadherence — not following a prescribed medical regimen — has been estimated to be in the billions of dollars of avoidable US health care costs each year. The FDA has now approved Otsuka’s Abilify MyCite (aripiprazole), an atypical antipsychotic for schizophrenia, bipolar I disorder, and depression in adults. The Abilify tablet formulation is embedded with the ingestible Proteus sensor that allows patients, and, if given access, doctors and caregivers, to track ingestion of the medication on a smartphone or web-based portal. The system sends a message from the pill’s sensor to a wearable patch on the patient, which then transmits to the device.

Posted: November 2017

Recommended for you

Tagged with:

About author

Related Articles